Independent cardiovascular risk factors: hyperhomocysteinemia and vascular stiffness in patients with hypertension
Keywords:homocysteine, H-type hypertension, pulse wave velocity, arterial stiffness
Background. Identification of risk factors and preliminary assessment of overall cardiovascular risk in patients with hypertension is the most important task in clinical practice. Most patients, in addition to high blood pressure (BP), have other cardiovascular risk factors that aggravate each other, leading to an increase in overall cardiovascular risk. One of the cardiovascular risk factors is an increased arterial stiffness. Arterial stiffness is evaluated using pulse wave velocity (PWV). The other independent risk factor for cardiovascular diseases is elevated level of total homocysteine in the blood. The purpose was to evaluate the relationship between hyperhomocysteinemia (HHc) and vascular stiffness in patients with hypertension. Materials and methods. Our research was carried out as a part of the ХІПСТЕР trial in Ukraine. The study included 40 patients with hypertension stage 1 and 2 (average office systolic (SBP)/diasto-lic blood pressure (DBP) was 155.88/92.60 ± 1.63/1.43 mmHg, heart rate — 71.40 ± 1.29 bpm). The average age of the patients was 55.85 ± 2.09 (26–74) years. Individuals with homocysteine levels ≥ 10 μmol/l were referred to as those with HHc
(H-type hypertension). Arterial stiffness was determined by PWV. Results. We found that at the beginning of the study, 75 %
of patients (30 individuals with mild and moderate hypertension) had H-type hypertension with an increased level of homocysteine. Patients with H-type hypertension (HHc) and hypertension without HHc did not differ in terms of age, duration of hypertension. At the same time, patients with H-type hypertension had higher body weight and body mass index. Office SBP in patients with H-type hypertension at baseline and after 6 months of treatment was higher compared to patients without HHc (156.45 ± 1.04 mmHg and 152.55 ±1.41 mmHg (p < 0.05) at baseline vs 130.65 ± 0.96 mmHg and 126.97 ± 1.08 mmHg (p < 0.05) in 6 months). At the beginning of the study, body mass index was 30.72 ± 0.39 kg/m2 in patients with H-type hypertension vs 28.34 ± 0.69 kg/m2 in those without HHc (p < 0.05). Patients with H-type hypertension less often achieved target blood pressure levels during treatment and initially had higher blood pressure values. Individuals with H-type hypertension compared to patients without HHc had a more severe insulin resistance (according to the homeostatic model assessment), lower glomerular filtration rate, both at baseline and by the end of treatment. According to ambulatory blood pressure monitoring data, before the start of treatment, patients with H-type hypertension compared to those with hypertension without HHc had a significantly higher SBP level. After regression analysis, homocysteine level was associated with PWVel, regardless of the degree of BP reduction (PWVel (6 months), m/s, b = 0.307, P = 0.001). Conclusions. Male gender, body mass index, glomerular filtration rate, blood glucose, office and central blood pressure were associated with elevated serum homocysteine levels.
Yingchoncharoen T., Limpijankit T., Jongjirasiri S., Laothamatas J., Yamwong S., Sritara P. Arterial stiffness contributes to coronary artery disease risk prediction beyond the traditional risk score (RAMA-EGAT score). Heart Asia. 2012. 4(1). 77-82. https://doi.org/10.1136/heartasia-2011-010079.
2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013. 34(28). 2159-2219. https://doi.org/10.1093/eurheartj/eht151.
Franklin S.S., Larson M.G., Khan S.A., Wong N.D., Leip E.P., Kannel W.B., Levy D. Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging? Circulation. 2001. 103(9). 1245-1249. https://doi.org/10.1161/01.cir.103.9.1245.
Wald D.S. Homocysteine and cardiovascular dise-ase: evidence on causality from a meta-analysis. BMJ. 2002. 325(7374). 1202-1206. https://doi.org/10.1136/bmj.325.7374.1202.
De Bree A., Mennen L.I., Zureik M., Ducros V., Guilland J.-C., Nicolas J.-P., Emery-Fillon N., Blacher J., Hercberg S., Galan P. Homocysteine is not associated with arterial thickness and stiffness in healthy middle-aged French volunteers. International Journal of Cardiology. 2006. 113(3). 332-340. https://doi.org/10.1016/j.ijcard.2005.11.045.
Vyssoulis G., Karpanou E., Kyvelou S.-M., Adamopoulos D., Gialernios T., Gymnopoulou E., Cokkinos D., Stefanadis C. Associations between plasma homocysteine levels, aortic stiffness and wave reflection in patients with arterial hypertension, isolated office hypertension and normotensive controls. Journal of Human Hypertension. 2009. 24(3). 183-189. https://doi.org/10.1038/jhh.2009.50.
Xiao W., Bai Y., Ye P., Luo L., Liu D., Wu H., Bai J. Plasma Homocysteine Is Associated with Aortic Arterial Stiffness but not Wave Reflection in Chinese Hypertensive Subjects. PLoS ONE. 2014. 9(1). e85938. https://doi.org/10.1371/journal.pone.0085938.
Zhang Q., Qiu D.-X., Fu R.-L., Xu T.-F., Jing M.-J., Zhang H.-S., Geng H.-H., Zheng L.-C., Wang P.-X. H-Type Hypertension and C Reactive Protein in Recurrence of Ischemic Stroke. International Journal of Environmental Research and Public Health. 2016. 13(5). 477. https://doi.org/10.3390/ijerph13050477.
Sirenko Yu.M., Rekovets O.L., Svischenko E.P., Ena L.M., Torbas E.A., Kushnir S.M., Gulkevych O.V., Mudruk I.V. Open clinical study of antihypertensive efficacy of generic drug telmisartan (hypotel) or a combination with S-amlodipine (Semlopin) or hydrochlorothiazide in the therapy of patients with mild to moderate arterial hypertension (ah) (results of the hipster. Hypertension. 2017. 0(1.51). 11-23. https://doi.org/10.22141/2224-14126.96.36.1997.96247.
Sirenko Yu.M., Rekovets O.L., Svischenko E.P., Ena L.M., Torbas E.A., Kushnir S.M., Gulkevych O.V., Mudruk I.V. Metabolic effects of the generic drug telmisartan (HYPotel) or its combination with S-amlodipine (Samlopin) or hydrochlorothiazide in the ThERapy of patients with mild to moderate arterial hypertension (results of the HYPSTER-AH study). Hypertension. 2017. 0(2.52). 69-83. https://doi.org/10.22141/2224-14188.8.131.527.101296.
Sen U., Mishra P.K., Tyagi N., Tyagi S.C. Homocysteine to Hydrogen Sulfide or Hypertension. Cell Biochemistry and Biophysics. 2010. 57(2–3). 49-58. https://doi.org/10.1007/s12013-010-9079-y.
Zhang W., Sun K., Chen J., Liao Y., Qin Q., Ma A., Wang D., Zhu Z., Wang Y., Hui R. High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. Clinical Science. 2009. 118(3). 187-194. https://doi.org/10.1042/cs20090142.
Xu G., Liu X., Wu W., Zhang R., Yin Q. Recurrence after Ischemic Stroke in Chinese Patients: Impact of Uncontrolled Modifiable Risk Factors. Cerebrovascular Diseases. 2006. 23(2–3). 117-120. https://doi.org/10.1159/000097047.
Aiyagari V., Badruddin A. Management of hypertension in acute stroke. Expert Review of Cardiovascular Therapy. 2009. 7(6). 637-646. https://doi.org/10.1586/erc.09.45.
Saposnik G., Ray J.G., Sheridan P., McQueen M., Lonn E. Homocysteine-Lowering Therapy and Stroke Risk, Severity, and Disability. Stroke. 2009. 40(4). 1365-1372. https://doi.org/10.1161/strokeaha.108.529503.
Leoo T., Lindgren A., Petersson J., von Arbin M. Risk Factors and Treatment at Recurrent Stroke Onset: Results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. Cerebrovascular Diseases. 2008. 25(3). 254-260. https://doi.org/10.1159/000113864.
Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattström L.E., Ueland P.M., Palma-Reis R.J., Boers G.H., Sheahan R.G., Israelsson B., Uiterwaal C.S., Meleady R., McMaster D., Verhoef P., Witteman J., Rubba P., Bellet H., Wautrecht J.C., de Valk H.W., Sales Lúis A.C. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997. 277(22). 1775-1781. https://doi.org/10.1001/jama.1997.03540460039030.
Zhou F., Hou D., Wang Y., Yu D. Evaluation of H-type hypertension prevalence and its influence on the risk of increased carotid intima-media thickness among a high-risk stroke population in Hainan Province, China. Medicine. 2020. 99(35). e21953. https://doi.org/10.1097/md.0000000000021953.
Qin X., Huo Y. H-Type hypertension, stroke and diabetes in China: Opportunities for primary prevention. Journal of Diabetes. 2015. 8(1). 38-40. https://doi.org/10.1111/1753-0407.12333.
Towfighi A., Markovic D., Ovbiagele B. Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: A nationwide study. Journal of the Neurological Sciences. 2010. 298(1–2). 153-157. https://doi.org/10.1016/j.jns.2010.07.013.
Zhang J., Liu Y., Wang A., Wang D., Jiang R., Jia J., Chen S., Zhao X. Association between H-type Hypertension and Asymptomatic Extracranial Artery Stenosis. Scientific Reports. 2018. 8(1). https://doi.org/10.1038/s41598-018-19740-0.
Qian G., Zeng L.-H., Liu Y.-Q., Cao F., Chen Y.-D., Zheng M.-L., Yang X.-C., Xu X.-P., Huo Y. Associations between plasma total homocysteine, blood pressure stages and pulse wave velocity in Chinese rural community population. Blood Pressure. 2015. 24(6). 340-346. https://doi.org/10.3109/08037051.2014.997089.
Chen L., Wang B., Wang J., Ban Q., Wu H., Song Y., Zhang J., Cao J., Zhou Z., Liu L., Cao T., Gao L., Guo H., Zhang T., Tang G., Huang X., Zhang Y., Li J., Huo Y., Cheng X. Association between serum total homocysteine and arterial stiffness in adults: a community-based study. The Journal of Clinical Hypertension. 2018. 20(4). 686-693. https://doi.org/10.1111/jch.13246.
Zhang S., Bai Y.-Y., Luo L.-M., Xiao W.-K., Wu H.-M., Ye P. Association between serum homocysteine and arterial stiffness in elderly: a community-based study. J. Geriatr. Cardiol. 2014 Mar. 11(1). 32-8. https://doi.org/10.3969/j.issn.1671-5411.2014.01.007.
Wang K., Wang Y., Chu C., Hu J., Zheng W., Yan Y., Ma Q., Gao K., Yuan Y., Mu J. Joint Association of Serum Homocysteine and High-Sensitivity C-Reactive Protein with Arterial Stiffness in Chinese Population: A 12-Year Longitudinal Study. Cardiology. 2019. 144(1–2). 27-35. https://doi.org/10.1159/000501742.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.